Related Experiment Video
Updated: Aug 9, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Sequential gene expression changes in cancer cell lines after treatment with the demethylation agent
Makoto Arai1, Osamu Yokosuka, Yuichi Hirasawa
1Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Background:
5-Aza-2'-deoxycytidine (5-AzaC) is known well for its demethylation effect and is a promising anticancer agent. However, to the authors' knowledge, serial changes in gene expression over time after 5-AzaC treatment have not been studied to date. To clarify the categories of genes that are up-regulated or down-regulated after 5-AzaC treatment, the authors surveyed the genes that had expression levels changed by 5-AzaC treatment in 6 hepatoma cell lines (Hep3B, HLE, Huh7, HepG2, PLC/PRF/5, and Huh6).
Methods:
Cell lines were grown in medium that contained 1 microM of 5-AzaC. Changes in messenger RNA levels were monitored from 24 hours up to 120 hours after 5-AzaC treatment using an in-house microarray that consisted of 4608 combinational DNAs. Using clustering analysis to identify the genes that had gradually changed expression levels and to exclude the substantial experimental noise by microarray analysis, the authors focused on 206 up-regulated genes and 248 down-regulated genes.
Results:
According to their functional characterization, genes that were involved in the cytoskeleton and the extracellular matrix were enriched significantly in the up-regulated genes. Conversely, genes that were involved in metabolism were enriched significantly in the down-regulated genes.
Conclusions:
The current results demonstrated that 5-AzaC can regulate the expression of groups of genes with characteristic functions.
Insights
This study reveals how 5-Aza-2'-deoxycytidine (5-AzaC) impacts gene expression in hepatoma cells over time. It identifies specific gene groups, including those in the cytoskeleton and metabolism, that are significantly altered by this promising anticancer agent.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- 5-Aza-2'-deoxycytidine (5-AzaC) is a demethylating agent with potential as an anticancer therapy.
- Previous research has not detailed the temporal gene expression changes induced by 5-AzaC.
- This study investigates gene expression alterations in six hepatoma cell lines following 5-AzaC treatment.
Purpose of the Study:
- To characterize the temporal dynamics of gene expression changes induced by 5-AzaC.
- To identify specific gene categories that are up-regulated or down-regulated by 5-AzaC treatment in hepatoma cells.
Main Methods:
- Hepatoma cell lines were treated with 1 microM 5-AzaC.
- Messenger RNA levels were analyzed using a 4608-element microarray over 120 hours.
- Clustering analysis identified 206 up-regulated and 248 down-regulated genes with gradual expression changes.
Main Results:
- Functional enrichment analysis revealed significant up-regulation of genes associated with the cytoskeleton and extracellular matrix.
- Genes involved in metabolic pathways were significantly down-regulated.
- 5-AzaC treatment induced distinct temporal expression patterns in specific gene sets.
Conclusions:
- 5-AzaC treatment systematically regulates the expression of functionally related gene groups in hepatoma cells.
- The findings provide insights into the molecular mechanisms of 5-AzaC's anticancer effects.
- This study highlights the potential of 5-AzaC in modulating cellular functions through gene expression regulation.
